What is Amniotics?
Founded in 2015 and based in Sweden, Amniotics is at the forefront of developing therapies utilizing mesenchymal stem cells sourced from amniotic fluid. The company's focus on this unique biological material positions it within the rapidly evolving biopharmaceutical landscape, aiming to address unmet medical needs through innovative cell-based treatments. The recent enterprise-level funding signifies a critical phase for the company's development and market penetration strategies.
How much funding has Amniotics raised?
Amniotics has raised a total of $526K across 1 funding round:
Unspecified
$526K
Unspecified (2022): $526K with participation from Sandra Lindstedt and Vinnova
Key Investors in Amniotics
Vinnova
Vinnova is Sweden's innovation agency, dedicated to enhancing Swedish innovation capacity and competitiveness for sustainable growth. The agency supports innovation that leads to sustainable solutions and system changes, particularly in the context of the green transition. Vinnova collaborates with various sectors and provides funding opportunities for projects that promote cross-border cooperation.
Sandra Lindstedt
Undisclosed investor participating in the funding round.
What's next for Amniotics?
With this significant strategic investment, Amniotics is poised for accelerated growth and the advancement of its therapeutic pipeline. The capital is expected to fuel further research and development, clinical trials, and potential expansion into new markets. This backing from strategic partners will likely enable Amniotics to scale its operations and solidify its position as a key player in the biopharma industry, particularly in the niche of amniotic fluid-derived stem cell therapies.
See full Amniotics company page
